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Deletions in the 4p16.3 region are associated with Wolf-Hirschhorn syndrome (WHS), a contiguous gene deletion syndrome
involving variable size deletions. In this study, we perform a cytogenomic integrative analysis combining classical cytogenetic
methods, fluorescence in situ hybridization (FISH), chromosomal microarray analysis (CMA), and systems biology strategies, to
establish the cytogenomic profile involving the 4p16.3 critical region and suggest WHS-related intracellular cell signaling cascades.
The cytogenetic and clinical patient profiles were evaluated. We characterized 12 terminal deletions, one interstitial deletion, two
ring chromosomes, and one classical translocation 4;8. CMA allowed delineation of the deletions, which ranged from 3.7 to 25.6Mb
with breakpoints from 4p16.3 to 4p15.33. Furthermore, the smallest region of overlapping (SRO) encompassed seven genes in a
terminal region of 330 kb in the 4p16.3 region, suggesting a region of susceptibility to convulsions and microcephaly. Therefore,
molecular interaction networks and topological analysis were performed to understand these WHS-related symptoms. Our results
suggest that specific cell signaling pathways including dopamine receptor, NAD+nucleosidase activity, and fibroblast growth factor-
activated receptor activity are associated with the diverse pathological WHS phenotypes and their symptoms. Additionally, we
identified 29 hub-bottlenecks (H-B) nodes with a major role in WHS.
1. Introduction
Wolf-Hirschhorn syndrome (WHS, OMIM #194190) is a
well known genetic condition with estimated prevalence of
1/20,000 to 1/50,000 births [1, 2] originally described inde-
pendently byHirschhorn andCooper [3] andWolf et al. [4] in
the 1960s.The core clinical features ofWHSare facial dysmor-
phia, growth retardation, intellectual disability, and seizures.
Moreover, other clinical signs such as microcephaly, hypoto-
nia, congenital heart defects, renal abnormalities, and skeletal
anomalies have also been reported [5]. WHS is caused by a
deletion in the p16.3 region (4p16.3), which has a variable size
that reflects the spectrum and severity of the disease [5–7].
Approximately 55% of individuals with WHS exhibit the
4p16.3 deletion and approximately 40–45% are unbalanced
translocations. Complex genomic rearrangements such as
ring 4 chromosome may also be present in a smaller number
of cases [6, 8].
The deleted region required to express the core WHS
phenotype has been reported to encompass two adjacent
critical regions.The first region described as theWHS critical
region (WHSCR) encompasses a size of 165 kb interval on
4p16.3 [9]. Two genes are present in this region, the proximal
part of WHSC1 and the negative elongation factor complex
member A (NELFA). WHSC1 is involved in controlling the
expression of several genes and acts as an agent in chromatin
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remodeling [10].TheNELFA gene alters the expression of tar-
get genes by participating in regulating the elongation of RNA
polymerase II transcription [11]. The second region is the
WHSCR2, which encompasses the leucine zipper-EF-hand-
containing transmembrane protein (LETM) gene and the 5󸀠
end of WHSC1 [12, 13]. LETM1 encodes a protein involved
in mitochondrial metabolism by transporting ions [14, 15].
Currently, the WHSCR is defined at chr4:419,224–2,010,962
position in the reference genome (NCBI BuildGRCh38/hg19)
[16].
The possibility of using microarrays to characterize chro-
mosomal rearrangements has led to several studies aimed at
establishing genotype-phenotype correlations in WHS, and
many of them have described the regions of susceptibility to
seizures and microcephaly in patients with WHS [1, 5, 17–
23]. However, no consensus has been reached on the exact
identity of the genes and cell signaling pathways involved
in promoting these symptoms. Therefore, we developed a
cytogenomic integrative analysis that combines conventional
cytogenetic techniques, chromosome microarray analysis
(CMA), and systems biology strategies to suggest the mecha-
nism underlying the seizures and microcephaly in WHS.
2. Materials and Methods
2.1. Study Design and Sample Selection. This was a retro-
spective study conducted on 16 samples from patients with
clinical suspicions of WHS. The patients were followed up at
the public genetic services in collaboration with the Brazilian
Network of Reference and Information for Microdeletion
Syndrome (RedeBRIM).
2.2. Cytogenetic Analysis. Karyotyping was performed on
metaphase spreads prepared from peripheral blood samples.
The chromosomal analysis was conducted afterGTGbanding
at a 550-band resolution, and at least 100 cells from each
patient were analyzed.
2.3. Fluorescence In Situ Hybridization (FISH). The fluores-
cence in situ hybridization (FISH) experiments were carried
out using standard techniques with commercially available
locus-specific probes using a dual-color commercial probe
for the WHSCR (Cytocell, UK). The probe for the 4p16.3
(red spectrum) contained a sequence that was homologous
to the D4S166 locus and covered approximately 223 kb of
this locus. The control probe for the 4q35.2 region (green
spectrum) contained sequences that were homologous to the
CTC-963K6 loci.
Hybridizations were analyzed using an epifluorescence
microscope, and the images were captured using a charge-
coupled device camera. At least 30 cells were analyzed
per hybridization. We considered a chromosome region as
deleted when the FISH signal from the corresponding probe
was absent from one of the homologous chromosomes.
2.4. CMA. The deletions were mapped using whole-genome
array-comparative genome hybridization (CGH) using a
60mer oligonucleotide-based microarray with a theoretical
resolution of 40 kb (8× 60K, Agilent Technologies Inc., Santa
Clara, CA, USA). The labeling and hybridization were per-
formed following the protocols provided byAgilent, 2011.The
arrays were analyzed using a microarray scanner (G2600D)
and the Feature Extraction software (version 9.5.1, both
from Agilent Technologies). The images were analyzed using
Cytogenomics v 2.0 and 2.7 with the statistical algorithm
ADM-2 and a sensitivity threshold of 6.0.
2.5. Systems Biology Analysis
2.5.1. Network Design. The Gene Multiple Association
Network Integration Algorithm (GeneMANIA) version
3.1.2.8 (available at http://www.genemania.org/) was used
to analyze the protein-protein interactions (PPI) networks
based on the 343 genes obtained from the GENCODE
V24–GRCh38/hg38-UCSC database. In the present study,
the association data from GeneMANIA was based on the
PPI databases, where each interaction between proteins
is experimentally proven [24], or on gene coexpression
data. The interactions based on known protein domains,
pathways, and colocalization were not considered in the
analysis because they could increase the false-positive
ratios in PPI networks obtained. The outcomes obtained
through these search engines were sequentially analyzed
using Cytoscape 3.4.1 [25]. Nonconnected nodes from the
networks were not included.
(1) Clustering. The MCODE tool was used to identify the
densely connected and possibly overlapping regions in the
Cytoscape network [26]. Dense regions corresponded to
protein or compound-protein complexes or their parts.Then,
Gene Ontology (GO) enrichment, Kyoto Encyclopedia of
Genes and Genomes (KEGG), WikiPathways, and Reactome
analyses were performed using the ClueGOCytoscape plugin
[27]. Based on the GO predictions, a cut-off of a p-corrected
value ≤ 0.01 using the false discovery rate (FDR) algorithm
(Bonferroni test) was used to describe the mechanisms as
described in the discussion section.
(2) Centralities. Two major parameters of network central-
ities (degree and betweenness) were used to identify the
hub-bottlenecks (H-B) nodes from the PPI network using
the Cytoscape plugin CentiScaPe 3.2.1 [28]. The degree of
centrality indicates the total number of adjacent nodes that
are connected to a unique node. In this study, the average
nodal degree of a network was defined as the sum of the
different node degree scores divided by the total number of
nodes that composed the entire network/s [29]. Furthermore,
we also analyzed the betweenness, which corresponds to
the number of shortest paths between two nodes that pass
through a node of interest [28]. The arithmetic average of the
betweenness parameterwas estimated similarly to the average
centrality degree [29].
2.6. Ethics Review. This study was approved by the Research
Ethics Committee of the Hospital de Cl´ınicas de Porto
Alegre (HCPA) with approval number GPPG 10-560 and was
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Figure 1: Karyotype results of (a) case 1 showing one normal chromosome 4 (left) and a chromosome 4p (right); (b) case 2, both normal
chromosomes 4; (c) case 4, a normal chromosome 4 (left) and a ring chromosome 4 (right) and fluorescence in situ hybridization (FISH)
results with locus-specific probes for the Wolf-Hirschhorn syndrome critical region (WHSCR) 4p16.3 from (d) case 1, (e) case 2, and (f) case
4. Absence of red signal on one copy of chromosome 4 indicates deletion of critical region.
conducted in accordance with all current institution ethical
rules.
3. Results and Discussion
A total of 16 samples from patients whose clinical phe-
notypes were indicative of WHS were retrospectively eval-
uated (supplementary material S1). Among the patients,
seven and nine (43.75 and 56.25%) were women and men,
respectively. The most frequent clinical findings in our
study group were seizures and microcephaly; however, facial
dysmorphia, growth retardation, and intellectual disability
were also observed (Table 1). In addition, the cytogenetic
and FISH analysis identified 12 classical terminal deletions,
one interstitial deletion, two ring chromosomes, and one
translocation t(4;8) (p16.3;p23.1, Figure 1). Furthermore, from
a total of 16 samples, the CMA was used to further map
eight deletions that occurred caused by terminal or interstitial
4p16.3 rearrangements. The deletions ranged in size from
3.7 to 26Mb (Figure 2(a)), and at least seven genes were
within the smallest region of overlapping (SRO) deletion in
the 4p16.3 region (Figure 2(b)). At the time of the present
study there were no DNA samples available to perform CMA
analysis from the further eight patients.
In our study, the SRO encompassed the 330 kb terminal
region of the short armof chromosome 4.This region extends
from 1.8 to 2.13Mb in the 4p16.3 region and it was identified
as a region of susceptibility to the convulsions and micro-
cephaly that are typical of WHS (Figure 2(b)). Comparing
the cytogenomic profile of our samples with that of other
studies, we delineated the proximal and distal breakpoints as
the SRO [1, 17] in the 4p16.3 region (Figure 3). This region
included seven candidate genes (LETM1, FGFR3, WHSC1,
NELFA, C4orf48, NAT8L, and POLN). These genes could
contribute to the pathogenic phenotype such as seizures and
microcephaly and include the LETM1 gene located in our
SRO, which contributes to the presence of seizures in a
hemizygous deletion [1, 12, 18, 30].
In human cell lines, the deletion of LETM1 could alter
the intracellular [Ca2+] levels, dysfunctional mitochondrial
transition-pore opening, and hyperpolarization [31, 32]. Fur-
thermore, thesemitochondrial alterations could contribute to
the emergence of some clinical findings in WHS including
seizures [31, 32]. All patients in this study presented seizure
symptoms, suggesting the putative involvement of this gene,
although patients with 4p deletions, including LETM1 with-
out seizures, or patients with seizures and the presence of
LETM1 have been described [1, 17, 23, 33, 34]. However,
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Figure 2: Cytogenomic profile of chromosome 4. (a) Red horizontal bars show extent of deleted segments on short arm of chromosome 4 in
eight samples investigated using array- comparative genome hybridization (CGH). (b) Genes on 4p16.3p15.33 with haploinsufficiency effects
associated with Wolf-Hirschhorn syndrome (WHS) clinical findings.
this may be partially explained by the synergism between
the phosphatidylinositol glycan anchor biosynthesis class G
(PIGG), complexin 1 (CPLX1), and LETM1 genes, frequently
associated with WHS convulsions [18].
Furthermore, our results showed a 330 kb region also
associated with microcephaly. The deletion of two genes,
WHSC1 and NELFA, in this region has already been associ-
ated with this condition [17, 19, 35].WHSC1 shows transcrip-
tional corepressor activity by expressing a histone methyl-
transferase [32, 36], which controls the level of histone H3
lysine 36 (H3K36) trimethylation and histone acetylation
[10]. NELFA encodes a member of the negative elongation
factor involved in regulating the progression of transcription
by RNA polymerase II [37] and histone mRNA maturation
into mRNAs [11]. The haploinsufficiency of NELFA in cell
lines from patients withWHS is associated with delayed pro-
gression from the S- into the M-phase and altered chromatin
assembly [35].
The following four additional genes are also located in
the susceptibility region proposed in this study, fibroblast
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Figure 3: Smallest region of overlapping (SRO) associated with microcephaly and seizures. Bars show deletion sizes and genomic position
on 4p. Red horizontal bars indicate seizures and microcephaly phenotype; green bars indicate absence of seizures and microcephaly, and
two bars in gray represent critical regions of Wolf-Hirschhorn syndrome (WHS). The smallest region of susceptibility to microcephaly and
seizures shown in this study is represented by blue bar, covering a 330 kb in size (1.8 to 2.13Mb).WHSCR,Wolf-Hirschhorn syndrome critical
region.
growth factor receptor 3 (FGFR3), N-acetyltransferase 8 like
(NAT8L), DNA polymerase Nu (POLN), and chromosome 4
open reading frame 48 (C4ORF48I). However, these genes
are not directly associated with seizures and microcephaly
but have a putative involvement in the skeletal development
and plasticity of the human brain [38–40]. In addition,
previous studies have described the occurrence of seizures,
microcephaly, or both, which indicates the contribution of
multiple deleted genes located adjacent to the SRO delineated
in our study [41].
Thus, focusing on the critical 4p16.3 chromosome region
mapped in our study, we explored the molecular inter-
action networks and biological pathways involving WHS-
associated genes. An initial list of 343 genes obtained from the
GENCODE V24-GRCh38/hg38-UCSC database was used
to construct an interactome network. This network was
composed of 136 nodes and 750 edges (Figure 4(a)). It is
important to note that for this initial network prediction we
considered a deletion of 26Mb including our SRO, WHSCR,
and WHSCR2 (Figure 2(a)). Furthermore, we performed
a cluster analysis that identified two major cluster regions,
cluster 1 (19 nodes and 56 edges) and cluster 2 (13 nodes
and 56 edges). In these clustered and unclustered nodes,
more significant GO categories were identified (Figure 4(a)).
In the unclustered nodes, four discrete molecular functions
were predicted: (1) NAD+ nucleosidase activity (𝑝 value
corrected = 0.002); (2) NAD(P)+ nucleosidase activity (𝑝
value corrected = 7.5 × 10−4). These pathways participate
in nicotinamide metabolism and calcium signaling, thereby
contributing to excitability, exocytosis, motility, apoptosis,
and cell transcriptionmechanisms [42, 43]; (3) FGFR activity
(𝑝 value corrected = 0.006) and (4) FGF binding (𝑝 value
corrected = 0.004), which is involved in the maintenance
of tissue homeostasis and regulation of metabolic processes
with specific roles such as the regulation of cell migration,
proliferation, and differentiation [44, 45].
The receptors involved in these pathways are encoded by
FGFR3 and FGFRL1, which interact with FGFs to activate
a downstream signaling cascade. The hemizygous deletions
of FGFR3 and FGFRL1 are implicated in the skeletal abnor-
malities and facial features typical of WHS [21, 46–48].
Furthermore, three GO categories were identified in cluster
1 (Figure 4(a)). The dopamine receptor signaling pathway (𝑝
value corrected = 0.001) has been implicated in numerous
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Figure 4: Graphs representing protein-protein interactions (PPI) network. (a) List of 343 genes was obtained from GENCODE V24-
GRCh38/hg38-UCSC database. The data was used to construct networks using Cytoscape software processing. (b) Centralities parameters
and topological analysis, using the CentiScaPe plugin; genes in small region overlapping (SRO) in our study are in red.
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neurological processes including sleep regulation, feeding,
attention, cognitive functions, olfaction, and hormonal reg-
ulation [49]. Toxin transport (𝑝 value corrected = 0.001) and
molecular functions such as nuclearDNAreplication (𝑝 value
corrected = 7.3 × 10−4) encompassing the stem-loop binding
protein (SLBP) andNELFA genes, often deleted inWHS,were
also predicted. It was not possible to predictGOandpathways
categories for cluster 2.
An alternative strategy to decipher cell signaling path-
ways involved in seizures and microcephaly using networks
is based on connectivity analysis. In this analysis, the
centrality properties were evaluated (Figure 4(b)), and 29
hub-bottlenecks (H-B) nodes were identified in the initial
network. The NELFA gene was localized in the SRO defined
in this study, and the SLBP gene was identified as an H-
B in the centrality analysis (Figure 4(b)). There is evidence
that NELFA is necessary for the recruitment of SLBP, by its
regulation of histone synthesis during the S-phase [11, 50].
Therefore, the haploinsufficiency of NELFA, SLBP, or both
could affect the cell-cycle progression, DNA replication, and
the chromatin assembly [35]. Interestingly, NELFA is located
in the WHSCR and SLBP in WHCR2, suggesting the inde-
pendent contribution of both genes in WHS pathogenesis.
The WHSC1 protein, also located in the SRO, affects
the levels of trimethylated H3K36 (H3K36Me3), which can
be reduced by siRNA-mediated knockdown of the NELF-
E component of the NELF complex [10, 51]. This indicates
another functional association between WHSC1 and NELFA
in controlling gene expression by chromatin remodeling and
regulation of the elongation of the transcription, respectively
[35]. The identification of the H-B NELFA, SLBP, and the
hubWHSC1 (Figure 4(b)) using centrality analysis highlights
the importance of the involvement of these genes in the
core WHS phenotype, such as skeletal malformation, facial
features, and microcephaly (Figure 2(b)) [1, 17, 19, 35, 52].
The centrality analysis revealed that 90% and 10% of the
H-B are located on chromosome 4 and other chromosomes,
respectively. Considering this evidence, we suggest that the
diversity of the pathological WHS phenotypes could be
dependent on interrelated and close H-Bs located on the
same chromosome. To the best of our knowledge, this is
the first report of a cytogenomic integrative network analysis
using systems biology to study the critical region associated
with WHS. Our study described the putative cell signaling
pathways altered in WHS that contribute to the integrative
understanding of the role of contiguous genes in the spec-
trum of this syndrome.
4. Conclusions
This study combined clinical data and integrative analysis
with conventional cytogenetic techniques, CMA, and systems
biology strategies. We confined the region of susceptibility
for microcephaly and seizures to a 330 kb sized region
that encompassed seven candidate genes (LETM1, FGFR3,
WHSC1, NELFA, C4orf48, NAT8LI, and POLN).The network
topological analysis identified 29 H-Bs, and the candidate
gene NELFA was included among these H-Bs. In addition,
significant GO categories showed that several cell signaling
pathways are responsible for the seizures and microcephaly
in WHS.
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